SCHEMBL2175671

SCHEMBL2175671

COC(=O)c1ccc2c(S(=O)(=O)Cl)cn(C)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SCN9A Q15858 8/20 0.42
SCN5A Q14524 2/20 0.42
BRD4 O60885 1/20 0.41
CREBBP Q92793 1/20 0.41
EDNRA P25101 1/20 0.41
CASP3 P42574 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
NR4A2 P43354 1/20 0.40
CYP1A2 P05177 1/20 0.40
TSHR P16473 1/20 0.40
CYP2C19 P33261 1/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
RECQL P46063 1/20 0.40
KMT2A Q03164 1/20 0.40
LCK P06239 1/20 0.40
CA12 O43570 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2175814 0.89 CPT2 (0.46) ALDH1A1L3MBTL1CASP3SMN1; SMN2NR4A2
SCHEMBL2178801 0.86 CA9 (0.45) SCN9ASCN5ABRD4CREBBPLCK
SCHEMBL17680562 0.81 NR4A2 (0.45) ALDH1A1SCN9ABRD4CREBBPCASP3
SCHEMBL19531634 0.78 SCN9A (0.58) SCN9ASCN5ABRD4CREBBPEDNRA
SCHEMBL19510180 0.77 MAPT (0.45) ALDH1A1SCN9ASCN5ABRD4CREBBP
SCHEMBL13806241 0.77 KDM4E (0.51) ALDH1A1L3MBTL1BRD4CREBBPCASP3
SCHEMBL31556362 0.77 MAPT (0.45) ALDH1A1SCN9ASCN5ABRD4CREBBP
SCHEMBL19475662 0.77 HSD17B10 (0.47) ALDH1A1L3MBTL1BRD4CREBBPCASP3
SCHEMBL31632933 0.77 HSD17B10 (0.47) ALDH1A1L3MBTL1BRD4CREBBPCASP3
SCHEMBL2495561 0.76 NR4A2 (0.54) ALDH1A1L3MBTL1BRD4CREBBPSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973051-B2 Aminothiazoles as FBPase inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2011-07-05 US disclosed
EP-2227468-A1 AMINOTHIAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-15 EP disclosed
US-20090143448-A1 NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-04 US disclosed
WO-2009068467-A1 AMINOTHIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143448-A1 NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES FBP1, SLC5A1, DPP4 ALDH1A1 525/4885L3MBTL1 3174/4885SCN9A 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.